RE: FitBio12 May 2019 16:36
Dracula1, regarding your "Just wondering how the IP of FitBio fits with Valirx IP. Seems a different field" query, surely this paragraph from the last RNS, explains the rationale:
"It is envisaged that ValiRx will provide the scientific, technological and clinical development expertise to the JV, whilst ABO will focus on financing the entity and progressing commercial activities. It is also envisaged that ValiRx will add its GeneICE technology, along with the Company's gene silencing compound, VAL101, into the JV portfolio to sit alongside the IP assets of FIT Bio, as the Company believes the portfolio technologies are complementary to each other. ValiRx's GeneICE technology has received two Eurostar awards to date for its technological development."
I see this as a good move to get VAL101 financed by ABO as per above statement.